{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T08:07:30Z","timestamp":1791187650690,"version":"4.1.0"},"reference-count":106,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s11904-010-0071-3","type":"journal-article","created":{"date-parts":[[2011,1,10]],"date-time":"2011-01-10T05:09:55Z","timestamp":1294636195000},"page":"12-22","source":"Crossref","is-referenced-by-count":185,"title":["HIV\/HCV Co-infection: Pathogenesis, Clinical Complications, Treatment, and New Therapeutic Technologies"],"prefix":"10.1007","volume":"8","author":[{"given":"Eva A.","family":"Operskalski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kovacs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,1,11]]},"reference":[{"issue":"1 Suppl","key":"71_CR1","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.jhep.2005.11.004","volume":"44","author":"MJ Alter","year":"2006","unstructured":"Alter MJ: Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006, 44(1 Suppl):S6\u20139.","journal-title":"J Hepatol"},{"issue":"3","key":"71_CR2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.cld.2005.05.003","volume":"9","author":"DL Thomas","year":"2005","unstructured":"Thomas DL and Seeff LB: Natural history of hepatitis C. Clin Liver Dis 2005, 9(3):383\u201398, vi.","journal-title":"Clin Liver Dis"},{"issue":"11","key":"71_CR3","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1089\/apc.2009.0111","volume":"23","author":"T Frederick","year":"2009","unstructured":"Frederick T, Burian P, Terrault N, et al.: Factors associated with prevalent hepatitis C infection among HIV-infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS 2009, 23(11):915\u201323.","journal-title":"AIDS Patient Care STDS"},{"issue":"4","key":"71_CR4","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1002\/hep.23808","volume":"52","author":"RA Tohme","year":"2010","unstructured":"Tohme RA and Holmberg SD: Is sexual contact a major mode of hepatitis C virus transmission? Hepatology 2010, 52(4):1497\u2013505.","journal-title":"Hepatology"},{"key":"71_CR5","doi-asserted-by":"crossref","unstructured":"van de Laar TJ, Paxton WA, Zorgdrager F, et al.: Sexual Transmission of Hepatitis C Virus in Human Immunodeficiency Virus-Negative Men Who Have Sex With Men: A Series of Case Reports. Sex Transm Dis 2010.","DOI":"10.1097\/OLQ.0b013e3181ec9de5"},{"issue":"14","key":"71_CR6","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMra065142","volume":"356","author":"MJ Koziel","year":"2007","unstructured":"Koziel MJ and Peters MG: Viral hepatitis in HIV infection. N Engl J Med 2007, 356(14):1445\u201354.","journal-title":"N Engl J Med"},{"issue":"9","key":"71_CR7","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1086\/592171","volume":"198","author":"V Soriano","year":"2008","unstructured":"Soriano V, Mocroft A, Rockstroh J, et al.: Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J Infect Dis 2008, 198(9):1337\u201344.","journal-title":"J Infect Dis"},{"issue":"1","key":"71_CR8","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1086\/509897","volume":"195","author":"T Laskus","year":"2007","unstructured":"Laskus T, Operskalski EA, Radkowski M, et al.: Negative-strand hepatitis C virus (HCV) RNA in peripheral blood mononuclear cells from anti-HCV-positive\/HIV-infected women. J Infect Dis 2007, 195(1):124\u201333.","journal-title":"J Infect Dis"},{"issue":"4","key":"71_CR9","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1365-2893.2009.01088.x","volume":"16","author":"S Moreno","year":"2009","unstructured":"Moreno S, Garcia-Samaniego J, Moreno A, et al.: Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV\/HBV co-infection. J Viral Hepat 2009, 16(4):249\u201358.","journal-title":"J Viral Hepat"},{"issue":"5","key":"71_CR10","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1365-2893.2009.01087.x","volume":"16","author":"L Castera","year":"2009","unstructured":"Castera L: Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009, 16(5):300\u201314.","journal-title":"J Viral Hepat"},{"issue":"Suppl 3","key":"71_CR11","doi-asserted-by":"crossref","first-page":"S279","DOI":"10.1086\/533414","volume":"197","author":"MS Sulkowski","year":"2008","unstructured":"Sulkowski MS: Management of hepatic complications in HIV-infected persons. J Infect Dis 2008, 197 Suppl 3:S279\u201393.","journal-title":"J Infect Dis"},{"issue":"3","key":"71_CR12","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1517\/14656560802694481","volume":"10","author":"K Neukam","year":"2009","unstructured":"Neukam K, Macias J, Mira JA, and Pineda JA: A review of current anti-HCV treatment regimens and possible future strategies. Expert Opin Pharmacother 2009, 10(3):417\u201333.","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"71_CR13","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2007.11.009","volume":"48","author":"MS Sulkowski","year":"2008","unstructured":"Sulkowski MS: Viral hepatitis and HIV coinfection. J Hepatol 2008, 48(2):353\u201367.","journal-title":"J Hepatol"},{"issue":"2","key":"71_CR14","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/S1473-3099(09)70020-9","volume":"9","author":"DP Webster","year":"2009","unstructured":"Webster DP, Klenerman P, Collier J, and Jeffery KJ: Development of novel treatments for hepatitis C. Lancet Infect Dis 2009, 9(2):108\u201317.","journal-title":"Lancet Infect Dis"},{"key":"71_CR15","unstructured":"\u2022 Franciscus A, (Editor): Hepatitis C treatments in current clinical development. HCV Advocate 2010. This is an annotated tabulated summary of HCV drugs in clinical development."},{"issue":"15","key":"71_CR16","doi-asserted-by":"crossref","first-page":"7366","DOI":"10.1128\/JVI.00191-09","volume":"83","author":"Y Rotman","year":"2009","unstructured":"Rotman Y and Liang TJ: Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol 2009, 83(15):7366\u201374.","journal-title":"J Virol"},{"key":"71_CR17","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1017\/S1462399408000847","volume":"10","author":"B Roe","year":"2008","unstructured":"Roe B and Hall WW: Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev Mol Med 2008, 10:e30.","journal-title":"Expert Rev Mol Med"},{"issue":"3","key":"71_CR18","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/j.gastro.2009.06.040","volume":"137","author":"AY Kim","year":"2009","unstructured":"Kim AY and Chung RT: Coinfection with HIV-1 and HCV\u2014a one-two punch. Gastroenterology 2009, 137(3):795\u2013814.","journal-title":"Gastroenterology"},{"issue":"5","key":"71_CR19","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2893.2008.00970.x","volume":"15","author":"JT Blackard","year":"2008","unstructured":"Blackard JT and Sherman KE: HCV\/ HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008, 15(5):323\u201330.","journal-title":"J Viral Hepat"},{"issue":"2","key":"71_CR20","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s11065-009-9101-6","volume":"19","author":"EM Martin-Thormeyer","year":"2009","unstructured":"Martin-Thormeyer EM and Paul RH: Drug abuse and hepatitis C infection as comorbid features of HIV associated neurocognitive disorder: neurocognitive and neuroimaging features. Neuropsychol Rev 2009, 19(2):215\u201331.","journal-title":"Neuropsychol Rev"},{"issue":"1","key":"71_CR21","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.antiviral.2009.10.021","volume":"85","author":"V Soriano","year":"2010","unstructured":"Soriano V, Vispo E, Labarga P, et al.: Viral hepatitis and HIV co-infection. Antiviral Res 2010, 85(1):303\u201315.","journal-title":"Antiviral Res"},{"issue":"10","key":"71_CR22","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1086\/644771","volume":"49","author":"TY Chen","year":"2009","unstructured":"Chen TY, Ding EL, Seage Iii GR, and Kim AY: Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009, 49(10):1605\u201315.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"71_CR23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1086\/603557","volume":"49","author":"A d\u2019Arminio Monforte","year":"2009","unstructured":"d\u2019Arminio Monforte A, Cozzi-Lepri A, Castagna A, et al.: Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis 2009, 49(4):612\u201322.","journal-title":"Clin Infect Dis"},{"key":"71_CR24","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Kovacs A, Karim R, Mack WJ, et al.: Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010, 201(6):823\u201334. This study showed that HCV-viremic women with HIV co-infection who have high levels of T-cell activation may have increased AIDS risk, and suggested that earlier treatment of HIV and HCV infections may be beneficial.","DOI":"10.1086\/650997"},{"issue":"10","key":"71_CR25","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1086\/587696","volume":"197","author":"A Kovacs","year":"2008","unstructured":"Kovacs A, Al-Harthi L, Christensen S, et al.: CD8(+) T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008, 197(10):1402\u20137.","journal-title":"J Infect Dis"},{"issue":"21","key":"71_CR26","doi-asserted-by":"crossref","first-page":"11407","DOI":"10.1128\/JVI.01211-09","volume":"83","author":"VD Gonzalez","year":"2009","unstructured":"Gonzalez VD, Falconer K, Blom KG, et al.: High levels of chronic immune activation in the T-cell compartments of patients coinfected with hepatitis C virus and human immunodeficiency virus type 1 and on highly active antiretroviral therapy are reverted by alpha interferon and ribavirin treatment. J Virol 2009, 83(21):11407\u201311.","journal-title":"J Virol"},{"issue":"12","key":"71_CR27","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1042\/CS20080532","volume":"116","author":"C Korner","year":"2009","unstructured":"Korner C, Kramer B, Schulte D, et al.: Effects of HCV co-infection on apoptosis of CD4+ T-cells in HIV-positive patients. Clin Sci (Lond) 2009, 116(12):861\u201370.","journal-title":"Clin Sci (Lond)"},{"issue":"12","key":"71_CR28","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1097\/QAD.0b013e32833adbb5","volume":"24","author":"M Potter","year":"2010","unstructured":"Potter M, Odueyungbo A, Yang H, et al.: Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIV-HCV coinfection before and after antiretroviral therapy. AIDS 2010, 24(12):1857\u201365.","journal-title":"AIDS"},{"issue":"5","key":"71_CR29","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1097\/QAI.0b013e318198a0e1","volume":"50","author":"L Peters","year":"2009","unstructured":"Peters L, Mocroft A, Soriano V, et al.: Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009, 50(5):457\u201363.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"7","key":"71_CR30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1089\/aid.2008.0069","volume":"24","author":"K Yacisin","year":"2008","unstructured":"Yacisin K, Maida I, Rios MJ, et al.: Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24(7):935\u201340.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"9","key":"71_CR31","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1086\/500843","volume":"193","author":"L Al-Harthi","year":"2006","unstructured":"Al-Harthi L, Voris J, Du W, et al.: Evaluating the impact of hepatitis C virus (HCV) on highly active antiretroviral therapy-mediated immune responses in HCV\/HIV-coinfected women: role of HCV on expression of primed\/memory T cells. J Infect Dis 2006, 193(9):1202\u201310.","journal-title":"J Infect Dis"},{"key":"71_CR32","unstructured":"\u2022\u2022 Panel on Antiretroviral Guidelines for Adults and Adolescents, Guidelines for the use of antiretroviral agents in HIV-1-infected adults and Adolescents. Department of Health and Human Services. 2009. p. 1\u2013161. These are recent US guidelines for antiretroviral therapy in HIV\/HCV co-infection."},{"issue":"15","key":"71_CR33","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","volume":"22","author":"HH Thein","year":"2008","unstructured":"Thein HH, Yi Q, Dore GJ, and Krahn MD: Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis. AIDS 2008, 22(15):1979\u201391.","journal-title":"AIDS"},{"issue":"11","key":"71_CR34","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1365-2893.2009.01133.x","volume":"16","author":"L Martin-Carbonero","year":"2009","unstructured":"Martin-Carbonero L, de Ledinghen V, Moreno A, et al.: Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection. J Viral Hepat 2009, 16(11):790\u20135.","journal-title":"J Viral Hepat"},{"issue":"6","key":"71_CR35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1089\/aid.2006.0085","volume":"23","author":"I Maida","year":"2007","unstructured":"Maida I, Soriano V, Barreiro P, et al.: Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfected patients with persistently normal transaminases. AIDS Res Hum Retroviruses 2007, 23(6):801\u20134.","journal-title":"AIDS Res Hum Retroviruses"},{"issue":"2","key":"71_CR36","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/QAI.0b013e31815d2f59","volume":"47","author":"C Smit","year":"2008","unstructured":"Smit C, van den Berg C, Geskus R, et al.: Risk of hepatitis-related mortality increased among hepatitis C virus\/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr 2008, 47(2):221\u20135.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"4","key":"71_CR37","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/hep.22134","volume":"47","author":"RK Sterling","year":"2008","unstructured":"Sterling RK, Contos MJ, Smith PG, et al.: Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus\/hepatitis C virus coinfection. Hepatology 2008, 47(4):1118\u201327.","journal-title":"Hepatology"},{"issue":"1","key":"71_CR38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/hep.23619","volume":"52","author":"MV Machado","year":"2010","unstructured":"Machado MV, Oliveira AG, and Cortez-Pinto H: Hepatic steatosis in patients coinfected with human immunodeficiency virus\/hepatitis C virus: a meta-analysis of the risk factors. Hepatology 2010, 52(1):71\u20138.","journal-title":"Hepatology"},{"issue":"2","key":"71_CR39","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QAD.0b013e3282f3553b","volume":"22","author":"T Kuntzen","year":"2008","unstructured":"Kuntzen T, Tural C, Li B, et al.: Intrahepatic mRNA expression in hepatitis C virus and HIV\/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART. AIDS 2008, 22(2):203\u201310.","journal-title":"AIDS"},{"issue":"7","key":"71_CR40","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1053\/j.gastro.2008.02.033","volume":"134","author":"N Nakamoto","year":"2008","unstructured":"Nakamoto N, Kaplan DE, Coleclough J, et al.: Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology 2008, 134(7):1927\u201337, 1937 e1\u20132","journal-title":"Gastroenterology"},{"issue":"10","key":"71_CR41","doi-asserted-by":"crossref","first-page":"e3454","DOI":"10.1371\/journal.pone.0003454","volume":"3","author":"B Vali","year":"2008","unstructured":"Vali B, Yue FY, Jones RB, et al.: HIV-specific T-cells accumulate in the liver in HCV\/HIV co-infection. PLoS One 2008, 3(10):e3454.","journal-title":"PLoS One"},{"issue":"1","key":"71_CR42","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1053\/j.gastro.2008.03.022","volume":"135","author":"A Balagopal","year":"2008","unstructured":"Balagopal A, Philp FH, Astemborski J, et al.: Human immunodeficiency virus-related microbial translocation and progression of hepatitis C. Gastroenterology 2008, 135(1):226\u201333.","journal-title":"Gastroenterology"},{"issue":"2","key":"71_CR43","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/hep.23679","volume":"52","author":"AC Tuyama","year":"2010","unstructured":"Tuyama AC, Hong F, Saiman Y, et al.: Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV\/hepatitis C virus-induced liver fibrosis. Hepatology 2010, 52(2):612\u201322.","journal-title":"Hepatology"},{"key":"71_CR44","unstructured":"Jang JY, Shao R-X, Lin W, et al.: HIV increases HCV-induced hepatocyte apoptosis. Journal of Hepatology In Press, Accepted Manuscript."},{"issue":"1","key":"71_CR45","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2036.2009.03995.x","volume":"30","author":"P Halfon","year":"2009","unstructured":"Halfon P, Penaranda G, Carrat F, et al.: Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther 2009, 30(1):61\u201370.","journal-title":"Aliment Pharmacol Ther"},{"issue":"12","key":"71_CR46","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1136\/gut.2009.179085","volume":"58","author":"N Merchante","year":"2009","unstructured":"Merchante N, Rivero A, de Los Santos-Gil I, et al.: Insulin resistance is associated with liver stiffness in HIV\/HCV co-infected patients. Gut 2009, 58(12):1654\u201360","journal-title":"Gut"},{"issue":"7","key":"71_CR47","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1086\/597350","volume":"48","author":"GD Kirk","year":"2009","unstructured":"Kirk GD, Astemborski J, Mehta SH, et al.: Assessment of liver fibrosis by transient elastography in persons with hepatitis C virus infection or HIV-hepatitis C virus coinfection. Clin Infect Dis 2009, 48(7):963\u201372.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"71_CR48","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/521857","volume":"45","author":"S Vergara","year":"2007","unstructured":"Vergara S, Macias J, Rivero A, et al.: The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2007, 45(8):969\u201374.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"71_CR49","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/ajg.2009.746","volume":"105","author":"D Nunes","year":"2010","unstructured":"Nunes D, Fleming C, Offner G, et al.: Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010, 105(6):1346\u201353.","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"71_CR50","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/QAI.0b013e318030ff8e","volume":"44","author":"H Al-Mohri","year":"2007","unstructured":"Al-Mohri H, Murphy T, Lu Y, et al.: Evaluating liver fibrosis progression and the impact of antiretroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007, 44(4):463\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"12","key":"71_CR51","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/QAD.0b013e328304dfe7","volume":"22","author":"DL Suzman","year":"2008","unstructured":"Suzman DL, McLaughlin M, Hu Z, et al.: Identification of novel markers for liver fibrosis in HIV\/hepatitis C virus coinfected individuals using genomics-based approach. AIDS 2008, 22(12):1433\u20139.","journal-title":"AIDS"},{"key":"71_CR52","doi-asserted-by":"crossref","unstructured":"Ghotb A, Noworolski SM, Madden E, et al.: Adipose tissue and metabolic factors associated with steatosis in HIV\/HCV coinfection: histology versus magnetic resonance spectroscopy. J Acquir Immune Defic Syndr 2010.","DOI":"10.1097\/QAI.0b013e3181e1d963"},{"issue":"8","key":"71_CR53","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1478-3231.2009.02052.x","volume":"29","author":"TW Lapinski","year":"2009","unstructured":"Lapinski TW, Parfieniuk A, Rogalska-Plonska M, et al.: Prevalence of cryoglobulinaemia in hepatitis C virus- and hepatitis C virus\/human immunodeficiency virus-infected individuals: implications for renal function. Liver Int 2009, 29(8):1158\u201361.","journal-title":"Liver Int"},{"issue":"2","key":"71_CR54","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1097\/QAI.0b013e3181685727","volume":"48","author":"J Reingold","year":"2008","unstructured":"Reingold J, Wanke C, Kotler D, et al.: Association of HIV infection and HIV\/HCV coinfection with C-reactive protein levels: the fat redistribution and metabolic change in HIV infection (FRAM) study. J Acquir Immune Defic Syndr 2008, 48(2):142\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"71_CR55","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1097\/QAI.0b013e3181b79aff","volume":"52","author":"KM Marks","year":"2009","unstructured":"Marks KM, Clarke RM, Bussel JB, et al.: Risk factors for thrombocytopenia in HIV-infected persons in the era of potent antiretroviral therapy. J Acquir Immune Defic Syndr 2009, 52(5):595\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"14","key":"71_CR56","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1097\/QAD.0b013e32830e0152","volume":"22","author":"CM Wyatt","year":"2008","unstructured":"Wyatt CM, Malvestutto C, Coca SG, et al.: The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis. AIDS 2008, 22(14):1799\u2013807.","journal-title":"AIDS"},{"issue":"2","key":"71_CR57","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/QAI.0b013e3181b980d4","volume":"53","author":"MJ Fischer","year":"2010","unstructured":"Fischer MJ, Wyatt CM, Gordon K, et al.: Hepatitis C and the risk of kidney disease and mortality in veterans with HIV. J Acquir Immune Defic Syndr 2010, 53(2):222\u20136.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"10","key":"71_CR58","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1097\/QAD.0b013e32832ac36a","volume":"23","author":"H Izzedine","year":"2009","unstructured":"Izzedine H, Sene D, Cacoub P, et al.: Kidney diseases in HIV\/HCV-co-infected patients. AIDS 2009, 23(10):1219\u201326.","journal-title":"AIDS"},{"issue":"7","key":"71_CR59","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1111\/j.1468-1293.2009.00815.x","volume":"11","author":"R Bedimo","year":"2010","unstructured":"Bedimo R, Westfall AO, Mugavero M, et al.: Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients. HIV Med 2010, 11(7):462\u20138.","journal-title":"HIV Med"},{"key":"71_CR60","unstructured":"Castro IF, Micheloud D, Berenguer J, et al.: Hepatitis C virus infection is associated with endothelial dysfunction in HIV\/hepatitis C virus coinfected patients. AIDS 2010."},{"issue":"3","key":"71_CR61","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1086\/519285","volume":"196","author":"S Letendre","year":"2007","unstructured":"Letendre S, Paulino AD, Rockenstein E, et al.: Pathogenesis of hepatitis C virus coinfection in the brains of patients infected with HIV. J Infect Dis 2007, 196(3):361\u201370.","journal-title":"J Infect Dis"},{"key":"71_CR62","doi-asserted-by":"crossref","unstructured":"Vivithanaporn P, Maingat F, Lin LT, et al.: Hepatitis C virus core protein induces neuroimmune activation and potentiates human immunodeficiency virus-1 neurotoxicity. PLoS One 2010, 5(9).","DOI":"10.1371\/journal.pone.0012856"},{"issue":"1","key":"71_CR63","first-page":"43","volume":"18","author":"HA Aronow","year":"2008","unstructured":"Aronow HA, Weston AJ, Pezeshki BB, and Lazarus TS: Effects of coinfection with HIV and hepatitis C virus on the nervous system. AIDS Read 2008, 18(1):43\u20138.","journal-title":"AIDS Read"},{"issue":"2","key":"71_CR64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1300\/J069v27n02_02","volume":"27","author":"CH Hinkin","year":"2008","unstructured":"Hinkin CH, Castellon SA, Levine AJ, et al.: Neurocognition in individuals co-infected with HIV and hepatitis C. J Addict Dis 2008, 27(2):11\u20137.","journal-title":"J Addict Dis"},{"issue":"6","key":"71_CR65","doi-asserted-by":"crossref","first-page":"e2516","DOI":"10.1371\/journal.pone.0002516","volume":"3","author":"P Ancuta","year":"2008","unstructured":"Ancuta P, Kamat A, Kunstman KJ, et al.: Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS One 2008, 3(6):e2516.","journal-title":"PLoS One"},{"issue":"4","key":"71_CR66","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1212\/WNL.0b013e3181af7a10","volume":"73","author":"DB Clifford","year":"2009","unstructured":"Clifford DB, Smurzynski M, Park LS, et al.: Effects of active HCV replication on neurologic status in HIV RNA virally suppressed patients. Neurology 2009, 73(4):309\u201314.","journal-title":"Neurology"},{"issue":"19","key":"71_CR67","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1212\/WNL.0b013e3181dd436d","volume":"74","author":"CL Cherry","year":"2010","unstructured":"Cherry CL, Affandi JS, Brew BJ, et al.: Hepatitis C seropositivity is not a risk factor for sensory neuropathy among patients with HIV. Neurology 2010, 74(19):1538\u201342.","journal-title":"Neurology"},{"issue":"10","key":"71_CR68","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1097\/QAD.0b013e32832bd7af","volume":"23","author":"AA Butt","year":"2009","unstructured":"Butt AA, McGinnis K, Rodriguez-Barradas MC, et al.: HIV infection and the risk of diabetes mellitus. AIDS 2009, 23(10):1227\u201334.","journal-title":"AIDS"},{"issue":"2","key":"71_CR69","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/QAI.0b013e3181d0c911","volume":"54","author":"AA Howard","year":"2010","unstructured":"Howard AA, Hoover DR, Anastos K, et al.: The effects of opiate use and hepatitis C virus infection on risk of diabetes mellitus in the Women\u2019s Interagency HIV Study. J Acquir Immune Defic Syndr 2010, 54(2):152\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"8","key":"71_CR70","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1097\/QAD.0b013e3283292195","volume":"23","author":"F Collin","year":"2009","unstructured":"Collin F, Duval X, Le Moing V, et al.: Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults. AIDS 2009, 23(8):1021\u20134.","journal-title":"AIDS"},{"issue":"8","key":"71_CR71","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/QAD.0b013e328329f994","volume":"23","author":"JF Pascual-Pareja","year":"2009","unstructured":"Pascual-Pareja JF, Caminoa A, Larrauri C, et al.: HAART is associated with lower hepatic necroinflammatory activity in HIV-hepatitis C virus-coinfected patients with CD4 cell count of more than 350 cells\/microl at the time of liver biopsy. AIDS 2009, 23(8):971\u20135.","journal-title":"AIDS"},{"issue":"2","key":"71_CR72","doi-asserted-by":"crossref","first-page":"e4517","DOI":"10.1371\/journal.pone.0004517","volume":"4","author":"EE Moodie","year":"2009","unstructured":"Moodie EE, Pant Pai N, and Klein MB: Is antiretroviral therapy causing long-term liver damage? A comparative analysis of HIV-mono-infected and HIV\/hepatitis C co-infected cohorts. PLoS One 2009, 4(2):e4517.","journal-title":"PLoS One"},{"key":"71_CR73","doi-asserted-by":"crossref","unstructured":"\u2022\u2022 Thompson MA, Aberg JA, Cahn P, et al.: Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010, 304(3):321\u201333. These are recent US guidelines for antiretroviral therapy in HIV\/HCV co-infection.","DOI":"10.1001\/jama.2010.1562"},{"issue":"11","key":"71_CR74","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1086\/593102","volume":"47","author":"E Tedaldi","year":"2008","unstructured":"Tedaldi E, Peters L, Neuhaus J, et al.: Opportunistic disease and mortality in patients coinfected with hepatitis B or C virus in the strategic management of antiretroviral therapy (SMART) study. Clin Infect Dis 2008, 47(11):1468\u201375.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"71_CR75","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/QAI.0b013e3181bd5ce1","volume":"53","author":"P Labarga","year":"2010","unstructured":"Labarga P, Vispo E, Barreiro P, et al.: Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV\/hepatitis C Virus coinfected patients with prior nonresponse or relapse. J Acquir Immune Defic Syndr 2010, 53(3):364\u20138.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"5","key":"71_CR76","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1086\/520092","volume":"196","author":"P Labarga","year":"2007","unstructured":"Labarga P, Soriano V, Vispo ME, et al.: Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 2007, 196(5):670\u20136.","journal-title":"J Infect Dis"},{"issue":"9","key":"71_CR77","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1097\/QAD.0b013e3281084e4d","volume":"21","author":"V Soriano","year":"2007","unstructured":"Soriano V, Puoti M, Sulkowski M, et al.: Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007, 21(9):1073\u201389.","journal-title":"AIDS"},{"issue":"8","key":"71_CR78","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s00431-008-0855-2","volume":"168","author":"K England","year":"2009","unstructured":"England K, Thorne C, Pembrey L, and Newell ML: Policies and practices for the clinical management of HIV\/HCV coinfected children in Europe: an epidemiological survey. Eur J Pediatr 2009, 168(8):915\u20137.","journal-title":"Eur J Pediatr"},{"key":"71_CR79","doi-asserted-by":"crossref","unstructured":"Iorio A, Marchesini E, Awad T, and Gluud LL: Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus. Cochrane Database Syst Rev 2010, (1):CD004888.","DOI":"10.1002\/14651858.CD004888.pub2"},{"issue":"8","key":"71_CR80","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1086\/597470","volume":"48","author":"E Eynde Van den","year":"2009","unstructured":"Van den Eynde E, Crespo M, Esteban JI, et al.: Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial. Clin Infect Dis 2009, 48(8):1152\u20139.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"71_CR81","first-page":"712","volume":"201","author":"KE Sherman","year":"2010","unstructured":"Sherman KE, Rouster SD, Stanford S, et al.: Hepatitis C virus (HCV) quasispecies complexity and selection in HCV\/HIV-coinfected subjects treated with interferon-based regimens. J Infect Dis 2010, 201(5):712\u20139.","journal-title":"J Infect Dis"},{"issue":"1","key":"71_CR82","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/QAD.0b013e3282f1da99","volume":"22","author":"L Martin-Carbonero","year":"2008","unstructured":"Martin-Carbonero L, Nunez M, Marino A, et al.: Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. AIDS 2008, 22(1):15\u201321.","journal-title":"AIDS"},{"issue":"1","key":"71_CR83","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/QAI.0b013e31815ac47d","volume":"47","author":"M Opravil","year":"2008","unstructured":"Opravil M, Sasadeusz J, Cooper DA, et al.: Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV\/hepatitis C virus coinfection. J Acquir Immune Defic Syndr 2008, 47(1):36\u201349.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"71_CR84","doi-asserted-by":"crossref","unstructured":"Mira JA, Gutierrez-Valencia A, Gil Ide L, et al.: Efficacy and safety of pegylated interferon plus ribavirin in HIV and hepatitis C virus-coinfected patients with advanced immunosuppression. Clin Infect Dis 2009, 49(8):e84\u201391.","DOI":"10.1086\/605677"},{"issue":"1","key":"71_CR85","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1365-2893.2008.01043.x","volume":"16","author":"B Felipe de","year":"2009","unstructured":"de Felipe B, Leal M, Soriano-Sarabia N, et al.: HCV RNA in peripheral blood cell subsets in HCV-HIV coinfected patients at the end of PegIFN\/RBV treatment is associated with virologic relapse. J Viral Hepat 2009, 16(1):21\u20137.","journal-title":"J Viral Hepat"},{"issue":"3","key":"71_CR86","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/QAI.0b013e3181c7a29d","volume":"53","author":"A Osinusi","year":"2010","unstructured":"Osinusi A, Rasimas JJ, Bishop R, et al.: HIV\/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do. J Acquir Immune Defic Syndr 2010, 53(3):357\u201363.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"71_CR87","doi-asserted-by":"crossref","unstructured":"Bhattacharya D, Umbleja T, Carrat F, et al.: Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. J Acquir Immune Defic Syndr 2010.","DOI":"10.1097\/QAI.0b013e3181e36420"},{"issue":"7","key":"71_CR88","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2893.2009.01102.x","volume":"16","author":"S Toma","year":"2009","unstructured":"Toma S, Yamashiro T, Arakaki S, et al.: Inhibition of intracellular hepatitis C virus replication by nelfinavir and synergistic effect with interferon-alpha. J Viral Hepat 2009, 16(7):506\u201312.","journal-title":"J Viral Hepat"},{"issue":"3","key":"71_CR89","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/135965350801300303","volume":"13","author":"E Vispo","year":"2008","unstructured":"Vispo E, Barreiro P, Pineda JA, et al.: Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther 2008, 13(3):429\u201337.","journal-title":"Antivir Ther"},{"issue":"1","key":"71_CR90","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3851\/IMP1492","volume":"15","author":"VK Amorosa","year":"2010","unstructured":"Amorosa VK, Slim J, Mounzer K, et al.: The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther 2010, 15(1):91\u20139.","journal-title":"Antivir Ther"},{"issue":"1","key":"71_CR91","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1086\/653214","volume":"202","author":"T Reiberger","year":"2010","unstructured":"Reiberger T, Kosi L, Maresch J, et al.: Mitochondrial toxicity is associated with virological response in patients with HIV and hepatitis C virus coinfection treated with ribavirin and highly active antiretroviral therapy. J Infect Dis 2010, 202(1):156-60.","journal-title":"J Infect Dis"},{"issue":"5","key":"71_CR92","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1086\/527565","volume":"46","author":"F Bani-Sadr","year":"2008","unstructured":"Bani-Sadr F, Lapidus N, Bedossa P, et al.: Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors. Clin Infect Dis 2008, 46(5):768\u201374.","journal-title":"Clin Infect Dis"},{"issue":"4","key":"71_CR93","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1128\/CMR.00015-09","volume":"22","author":"P Price","year":"2009","unstructured":"Price P, Murdoch DM, Agarwal U, et al.: Immune restoration diseases reflect diverse immunopathological mechanisms. Clin Microbiol Rev 2009, 22(4):651-63.","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"71_CR94","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/MAJ.0b013e31811ec780","volume":"334","author":"I Ofotokun","year":"2007","unstructured":"Ofotokun I, Smithson SE, Lu C, et al.: Liver enzymes elevation and immune reconstitution among treatment-naive HIV-infected patients instituting antiretroviral therapy. Am J Med Sci 2007, 334(5):334\u201341.","journal-title":"Am J Med Sci"},{"issue":"5","key":"71_CR95","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/QAD.0b013e328013db9c","volume":"21","author":"P Cicconi","year":"2007","unstructured":"Cicconi P, Cozzi-Lepri A, Phillips A, et al.: Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy? AIDS 2007, 21(5):599\u2013606.","journal-title":"AIDS"},{"issue":"2","key":"71_CR96","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/hep.22357","volume":"48","author":"PJ Pockros","year":"2008","unstructured":"Pockros PJ, Nelson D, Godofsky E, et al.: R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin. Hepatology 2008, 48(2):385\u201397.","journal-title":"Hepatology"},{"issue":"2","key":"71_CR97","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/hep.22321","volume":"48","author":"SK Roberts","year":"2008","unstructured":"Roberts SK, Cooksley G, Dore GJ, et al.: Robust antiviral activity of R1626, a novel nucleoside analog: a randomized, placebo-controlled study in patients with chronic hepatitis C. Hepatology 2008, 48(2):398\u2013406.","journal-title":"Hepatology"},{"issue":"6","key":"71_CR98","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1128\/AAC.01599-08","volume":"53","author":"ST Shi","year":"2009","unstructured":"Shi ST, Herlihy KJ, Graham JP, et al.: Preclinical characterization of PF-00868554, a potent nonnucleoside inhibitor of the hepatitis C virus RNA-dependent RNA polymerase. Antimicrob Agents Chemother 2009, 53(6):2544\u201352.","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"71_CR99","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1021\/jm800940u","volume":"52","author":"S Venkatraman","year":"2009","unstructured":"Venkatraman S, Velazquez F, Wu W, et al.: Discovery and structure-activity relationship of P1-P3 ketoamide derived macrocyclic inhibitors of hepatitis C virus NS3 protease. J Med Chem 2009, 52(2):336\u201346.","journal-title":"J Med Chem"},{"issue":"5","key":"71_CR100","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1021\/jm8014537","volume":"52","author":"H Li","year":"2009","unstructured":"Li H, Tatlock J, Linton A, et al.: Discovery of (R)-6-cyclopentyl-6-(2-(2,6-diethylpyridin-4-yl)ethyl)-3-((5,7-dimethyl-[1 ,2,4]triazolo[1,5-a]pyrimidin-2-yl)methyl)-4-hydroxy-5,6-dihydropyran-2-on e (PF-00868554) as a potent and orally available hepatitis C virus polymerase inhibitor. J Med Chem 2009, 52(5):1255\u20138.","journal-title":"J Med Chem"},{"issue":"Suppl","key":"71_CR101","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1665-2681(19)31737-5","volume":"9","author":"M Rodriguez-Torres","year":"2010","unstructured":"Rodriguez-Torres M: On the cusp of change: new therapeutic modalities for HCV. Ann Hepatol 2010, 9 Suppl:123\u201331.","journal-title":"Ann Hepatol"},{"issue":"8","key":"71_CR102","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/s12325-010-0047-0","volume":"27","author":"AJ Fowell","year":"2010","unstructured":"Fowell AJ and Nash KL: Telaprevir: a new hope in the treatment of chronic hepatitis C? Adv Ther 2010, 27(8):512\u201322.","journal-title":"Adv Ther"},{"issue":"4","key":"71_CR103","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1002\/hep.23827","volume":"52","author":"F Poordad","year":"2010","unstructured":"Poordad F, Lawitz E, Shiffman ML, et al.: Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C. Hepatology 2010, 52(4):1208\u201315.","journal-title":"Hepatology"},{"issue":"1","key":"71_CR104","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1097\/QAD.0b013e32831940a3","volume":"23","author":"EC Thomson","year":"2009","unstructured":"Thomson EC, Nastouli E, Main J, et al.: Delayed anti-HCV antibody response in HIV-positive men acutely infected with HCV. AIDS 2009, 23(1):89\u201393.","journal-title":"AIDS"},{"issue":"5","key":"71_CR105","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1086\/596770","volume":"48","author":"GV Matthews","year":"2009","unstructured":"Matthews GV, Hellard M, Haber P, et al.: Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis C. Clin Infect Dis 2009, 48(5):650\u20138.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"71_CR106","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1086\/600399","volume":"49","author":"J Schulze Zur Wiesch","year":"2009","unstructured":"Schulze Zur Wiesch J, Pieper D, Stahmer I, et al.: Sustained virological response after early antiviral treatment of acute hepatitis C virus and HIV coinfection. Clin Infect Dis 2009, 49(3):466\u201372.","journal-title":"Clin Infect Dis"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11904-010-0071-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T22:19:43Z","timestamp":1712096383000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11904-010-0071-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,11]]},"references-count":106,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["71"],"URL":"https:\/\/doi.org\/10.1007\/s11904-010-0071-3","relation":{},"ISSN":["1548-3568","1548-3576"],"issn-type":[{"value":"1548-3568","type":"print"},{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,11]]}}}